Registered number
14276048
MHS PHARMS LTD
Filleted Accounts
31 March 2024
MHS PHARMS LTD
Registered number: 14276048
Balance Sheet
as at 31 March 2024
Notes 2024 2023
£ £
Fixed assets
Tangible assets 3 3,169 900
Current assets
Debtors 4 7,429 8,720
Cash at bank and in hand 17,986 10,897
25,415 19,617
Creditors: amounts falling due within one year 5 (15,041) (8,454)
Net current assets 10,374 11,163
Total assets less current liabilities 13,543 12,063
Creditors: amounts falling due after more than one year 6 (2,491) (4,675)
Net assets 11,052 7,388
Capital and reserves
Called up share capital 100 100
Profit and loss account 10,952 7,288
Shareholder's funds 11,052 7,388
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
MOHAMMAD HAMZA SADIQ
Director
Approved by the board on 2 August 2024
MHS PHARMS LTD
Notes to the Accounts
for the year ended 31 March 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 10 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 1 1
3 Tangible fixed assets
Plant and machinery
£
Cost
At 1 April 2023 1,000
Additions 2,633
At 31 March 2024 3,633
Depreciation
At 1 April 2023 100
Charge for the year 364
At 31 March 2024 464
Net book value
At 31 March 2024 3,169
At 31 March 2023 900
4 Debtors 2024 2023
£ £
Trade debtors 7,429 8,720
5 Creditors: amounts falling due within one year 2024 2023
£ £
Corporation Tax 10,002 4,360
Other creditors 5,039 4,094
15,041 8,454
6 Creditors: amounts falling due after one year 2024 2023
£ £
Directors Loan 2,491 4,675
7 Controlling party
The company is under the full control of the director by virtue of them owning 100% of the issued share capital.
8 Other information
MHS PHARMS LTD is a private company limited by shares and incorporated in England. Its registered office is:
110-112 Yews Hill Road
Huddersfield
HD1 3SG
MHS PHARMS LTD 14276048 false 2023-04-01 2024-03-31 2024-03-31 VT Final Accounts April 2024 MOHAMMAD HAMZA SADIQ No description of principal activity 14276048 2022-08-04 2023-03-31 14276048 core:WithinOneYear 2023-03-31 14276048 core:AfterOneYear 2023-03-31 14276048 core:ShareCapital 2023-03-31 14276048 core:RetainedEarningsAccumulatedLosses 2023-03-31 14276048 2023-04-01 2024-03-31 14276048 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 14276048 bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 14276048 bus:Director40 2023-04-01 2024-03-31 14276048 1 2023-04-01 2024-03-31 14276048 2 2023-04-01 2024-03-31 14276048 core:PlantMachinery 2023-04-01 2024-03-31 14276048 countries:England 2023-04-01 2024-03-31 14276048 bus:FRS102 2023-04-01 2024-03-31 14276048 bus:FilletedAccounts 2023-04-01 2024-03-31 14276048 2024-03-31 14276048 core:WithinOneYear 2024-03-31 14276048 core:AfterOneYear 2024-03-31 14276048 core:ShareCapital 2024-03-31 14276048 core:RetainedEarningsAccumulatedLosses 2024-03-31 14276048 core:PlantMachinery 2024-03-31 14276048 2023-03-31 14276048 core:PlantMachinery 2023-03-31 iso4217:GBP xbrli:pure